Close Menu

DeciBio

Data amassed by analytics firm Diaceutics suggests fewer patients are coming into healthcare facilities and missing the chance for diagnosis, molecular testing, and treatment.

The market for next-generation sequencing-based molecular diagnostic tests is poised to grow more than tenfold between 2012 and 2015, driven by non-invasive prenatal and oncology tests, most of them targeted, according to a recent report from research firm DeciBio.

Next-generation sequencing is helping to drive the emerging market in single-cell genomics, according to a report by Culver City, Calif.-based market research firm DeciBio.

The next-generation sequencing market is poised to grow 20 percent per year from around $1.2 billion currently to $2.1 billion by 2015, driven in large part by desktop sequencers, according to a recent report by Los Angeles-based market research firm DeciBio.

Fluidigm's product revenues are expected to grow 27 percent annually over the next four years, buoyed by the company's participation in three rapidly growing niche markets — sample preparation for next-gen sequencing, single-cell genomics, and digital PCR — according to a market

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.